New Approaches to Measuring Value in Oncology Therapy
Although clinical trial data have quantified patient survival gains associated with tyrosine kinase inhibitors in chronic myeloid leukemia, the overall value of these benefits is unknown.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug
2
GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis
3
Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care
4
Sarcoma Gene Signature May Predict Who Benefits From Pazopanib
5